Exelixis.
American biotechnology company
- Reports this week
- 1
- Active events
- 1
- Connections
- 97
What's happening
Active this week
Earlier this month
-
Mary Beckerle is a director of Exelixis, and the SEC is tracking institutional filings regarding the company's stock.Some support1 report
-
Exelixis and SAB Biotherapeutics are competing for investment as healthcare companies.Some support1 report
-
Barclays and UBS raised price targets for Exelixis stock, noting that AI stocks are benefiting from Trump-era tariffs.Some support2 reports
One to three months ago
-
Royal Bank of Canada trimmed its price target for Exelixis in a research report.Some support1 report
-
Morgan Stanley provided positive research ratings on Exelixis stock, with MarketBeat aggregating the consensus data.Some support4 reports
-
GRAIL and Exelixis, both healthcare companies, are competing for investment.Some support1 report
-
The FDA has delayed potential approval of a cancer treatment that utilizes Exelixis in combination with Roche's Tecentriq.Some support1 report
-
Exelixis stock trades on the Nasdaq electronic stock exchange.Some support1 report
-
TD Cowen raised its price target on Exelixis shares on August 30, 2026.Some support1 report
-
NET revenue ramp slows, Exelixis drug is under FDA review, and Ipsen receives royalties from cabozantinib sales.Some support3 reports
Gone quiet
No new reports in 90+ days-
Truist Financial adjusted its rating and TD Cowen lifted its target price for Exelixis stock.Some support2 reports
-
Exelixis insiders sold shares and filed the required disclosure with the SEC on July 1, 2026.Some support1 report
-
Exelixis filed required disclosures regarding share holdings with the Securities and Exchange Commission.Some support1 report
-
Zacks Analyst Blog recommended Exelixis and Sprouts Farmers Market, while gold prices drove safe-haven demand for Royal Gold.Speculative1 report
-
The new event lists the headquarters and operational areas for Exelixis, Kinross Gold, and Lyft.Speculative2 reports
-
Cabometyx drove strong financial results for Exelixis in July 2025.Some support2 reports
-
Zacks Investment Research provided stock analysis and rankings for Exelixis on July 4, 2025. The company is based in Alameda, CA.Speculative3 reports
-
A collaboration between Bristol-Myers Squibb and Exelixis is seeking FDA clearance for an IND application regarding combination therapies.Some support1 report1 development inside
-
Cabometyx was approved in combination with BMY's Opdivo, and Merck supplied Keytruda for an Exelixis study.Speculative1 report
-
Exelixis operates within the biomedical and genetics industry.Some support6 reports
-
Ipsen contributed royalties to Exelixis's collaboration revenues following the launch of CABOMETYX for NETs.Some support2 reports1 development inside
-
Exelixis and argenex SE are identified as stocks within the medical and biomedical investment sector.Some support1 report
-
Exelixis stock performance on July 23, 2025, contrasted with the movement of the S&P 500.Some support2 reports
-
Exelixis captured market share in NET and Morrissey was named CEO on July 29, 2025.Some support1 report
-
Exelixis received a rating upgrade following an upward trend in earnings estimates, which institutional investors use for valuation.Some support2 reports
-
Celestica and Exelixis were reported as highly ranked stocks following their Q2 earnings reports in July 2025.Some support1 report
-
The National Cancer Institute (NCI) has been associated with Exelixis since July 30, 2025.Some support1 report
-
Exelixis reported on August 4, 2025, that Europe contributed 6.5% of its total revenue, alongside 1.1% from Japan.Some support1 report
-
Exelixis's CABOMETYX received FDA approval for neuroendocrine tumors (NET) on September 5, 2025.Some support3 reports
-
Exelixis conducted the STELLAR-305 trial, investigating zanzalintinib and pembrolizumab, while Robert Burns maintained a Buy rating.Some support1 report
-
Zacks Investment Research provided stock analysis and recommendations for Exelixis on August 30, 2025.Some support1 report
-
Dana T. Aftab was appointed Executive Vice President, R&D at Exelixis on August 30, 2025.Some support1 report
-
Exelixis, a company, is headquartered in Alameda, California.Well supported5 reports
No events began in the chosen period. Widen it, or reset.
Around Exelixis this week
News at the entities that move Exelixis most-
FDA StructuralFDA approved a drug based on UVA research led by Xuemei Huang.Moves Exelixis
-
Securities and Exchange Commission StructuralRothschild Wealth LLC purchased a new stake in the Distillate Small/Mid Cash Flow ETF, which subsequently filed required reports with the SEC.Moves Exelixis
-
Morgan Stanley OperationalMorgan Stanley raised its stock price target for Disney+ on November 10, 2026.Moves Exelixis
-
Food and Drug Administration StructuralAnthropic and OpenAI CEOs urged an industry slowdown call, while the FDA issued guidance for AI medical devices and Change Healthcare suffered a major ransomware attack.Moves Exelixis
-
Hoffmann-La Roche OperationalMajor pharmaceutical companies licensed drug delivery technologies like Enhanze and Hypercon for various applications.Moves Exelixis
-
SEC StructuralFrontier disclosed major shareholder transactions involving its SVP via an SEC filing on July 27, 2026, while the company is listed on the Nasdaq stock exchange.Moves Exelixis
Connections
The 27 strongest of 97, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Andrew Brown Structural
Andrew Brown is a founding partner of Exelixis, establishing a foundational and ongoing professional link.
-
Ipsen Operational
Ipsen and Exelixis maintain an operational partnership involving supply and collaboration revenue sharing.
-
FDA Structural
FDA regulates and grants market approvals for Exelixis' pharmaceutical products.
-
Securities and Exchange Commission Structural
Exelixis is subject to mandatory regulatory oversight by the SEC regarding its market disclosures.
-
Hoffmann-La Roche Operational
Exelixis utilizes Roche's Tecentriq product as part of a combined therapeutic approach.
-
Morgan Stanley Operational
Morgan Stanley actively influences Exelixis through research ratings and financial investments, while Exelixis participates in MS events.
-
Mary Beckerle Structural
Mary Beckerle holds a formal governance role as a director of Exelixis.
-
Andrew Peters Structural
Andrew Peters holds the functional role of Senior Vice President of Strategy for Exelixis.
Show all 27 connections
-
Ipsen Structural
Ipsen receives royalties from cabozantinib sales, indicating a structural financial dependency on Exelixis's product.
-
SEC Structural
Exelixis operates under regulatory requirements and filing mandates enforced by the SEC.
-
Food and Drug Administration Structural
The FDA regulates Exelixis, impacting the approval and market status of its cancer treatments.
-
NET Operational
Exelixis is actively competing with NET by capturing market share and treating the same neuroendocrine tumors.
-
Truist Financial Mentioned together
Truist Financial provides stock ratings and price targets for Exelixis.
-
Merck Operational
Exelixis and Merck actively compete in the renal cell carcinoma market and engage in collaborative research studies.
-
Michael Morrissey Structural
Michael Morrissey serves as the CEO of Exelixis, leading the company through business challenges.
-
TD Cowen Mentioned together
TD Cowen issues analyst reports that raise its price target and objective for Exelixis stock.
-
GRAIL Operational
Both companies are healthcare entities that compete for investment in the market.
-
Citigroup Mentioned together
Citigroup provides market research and ratings coverage on Exelixis.
-
Leerink partners Transactional
Leerink partners issued a negative stock rating for Exelixis.
-
David Schwartz Operational
A is under investigation for securities law violations related to Exelixis' market operations and investor losses.
-
MarketBeat Mentioned together
MarketBeat aggregates consensus rating data specifically for Exelixis.
-
Wells Mentioned together
Exelixis participated in a biotech session hosted by Wells.
-
Alameda Shared context
A is headquartered in Alameda, California, providing the shared geographical context for the relationship with B.
-
William P. Blair Mentioned together
William Blair provided a rating assessment on Exelixis.
-
Nasdaq Shared context
Exelixis is listed and trades on the Nasdaq electronic stock exchange.
-
Andy Hsieh Mentioned together
A single analyst prediction noted an unlikely outright rejection related to the entities.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada provides financial research coverage, including price targets, for Exelixis.
History
Events by the month they beganNovember 2026
2 eventsOctober 2026
2 eventsSeptember 2026
3 eventsShow 3 earlier months
August 2026
3 eventsJuly 2026
2 eventsJune 2026
22 events- Barclays and UBS raised price targets for Exelixis stock, noting that AI stocks are benefiting from Trump-era tariffs.
- Exelixis filed required disclosures regarding share holdings with the Securities and Exchange Commission.
- Zacks Analyst Blog recommended Exelixis and Sprouts Farmers Market, while gold prices drove safe-haven demand for Royal Gold.
- The new event lists the headquarters and operational areas for Exelixis, Kinross Gold, and Lyft.
- Cabometyx drove strong financial results for Exelixis in July 2025.
- Zacks Investment Research provided stock analysis and rankings for Exelixis on July 4, 2025. The company is based in Alameda, CA.
- A collaboration between Bristol-Myers Squibb and Exelixis is seeking FDA clearance for an IND application regarding combination therapies.
- Cabometyx was approved in combination with BMY's Opdivo, and Merck supplied Keytruda for an Exelixis study.
- Exelixis operates within the biomedical and genetics industry.
- Ipsen contributed royalties to Exelixis's collaboration revenues following the launch of CABOMETYX for NETs.
- Exelixis and argenex SE are identified as stocks within the medical and biomedical investment sector.
- Exelixis stock performance on July 23, 2025, contrasted with the movement of the S&P 500.
- Exelixis captured market share in NET and Morrissey was named CEO on July 29, 2025.
- Exelixis received a rating upgrade following an upward trend in earnings estimates, which institutional investors use for valuation.
- Celestica and Exelixis were reported as highly ranked stocks following their Q2 earnings reports in July 2025.
- The National Cancer Institute (NCI) has been associated with Exelixis since July 30, 2025.
- Exelixis reported on August 4, 2025, that Europe contributed 6.5% of its total revenue, alongside 1.1% from Japan.
- Exelixis's CABOMETYX received FDA approval for neuroendocrine tumors (NET) on September 5, 2025.
- Exelixis conducted the STELLAR-305 trial, investigating zanzalintinib and pembrolizumab, while Robert Burns maintained a Buy rating.
- Zacks Investment Research provided stock analysis and recommendations for Exelixis on August 30, 2025.
- Dana T. Aftab was appointed Executive Vice President, R&D at Exelixis on August 30, 2025.
- Exelixis, a company, is headquartered in Alameda, California.